FDA: Screen genes before taking Tegretol

If you need more evidence that individualized drug therapy is the next frontier, look no further. The FDA has issued a new warning on carbamazepine, an epilepsy-slash-bipolar drug that can cause rare but severe side effects in certain patients of Asian descent. Before using the drug--marketed as Tegretol by Novartis and Equetro by Validus Pharmaceuticals--patients of Asian ancestry should undergo genetic testing, the agency said.

The black-box warning will alert patients to the potential for Stevens-Johnson syndrome and for toxic epidermal necrolysis, both severe skin reactions.

The FDA's genetic-testing recommendation is among its first. The agency previously has alerted healthcare providers to specific genetic variations and their effect on patients' response to particular drugs. A few months ago, the agency suggested that patients be tested for certain genetic variances before taking the blood thinner warfarin.

- here's the warning from the FDA
- read the report in The Wall Street Journal

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.